Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Titel:
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Auteur:
Meng, Xiangrui Wang, Junsheng Xia, Jin Wu, Tao Luo, Zhiquan Hong, Yonggui Lu, Ping Guo, Yanzhen Ji, Yinghua Zhang, Min Yang, Liuzhong Cheng, Peng Liang, Wenchang Shan, Zhengzheng Zhou, Yue Wang, Mingyue Lu, Taiying Song, Min Zong, Hong Song, Lijie Wang, Wenkang Guan, Lulu Li, Yanke Xing, Jianxiang Xing, Siyuan Wu, Han Chu, Jingwen Luo, Xi Lu, Yao Xin, Dao Li, Aijia Jiang, Binghua Li, Shenglei Jiang, Guozhong Fan, Qingxia Zhao, Feng Zheng, Rongrong Zhu, Wenqing Hou, Zhiguo Jia, Yun Wang, Feng